Aclaris Therapeutics (ACRS) Payables (2017 - 2025)
Historic Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $9.2 million.
- Aclaris Therapeutics' Payables rose 1990.34% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 1990.34%. This contributed to the annual value of $4.7 million for FY2024, which is 4717.28% down from last year.
- Latest data reveals that Aclaris Therapeutics reported Payables of $9.2 million as of Q3 2025, which was up 1990.34% from $8.8 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Payables ranged from a high of $11.4 million in Q2 2023 and a low of $4.2 million during Q2 2021
- For the 5-year period, Aclaris Therapeutics' Payables averaged around $8.1 million, with its median value being $8.1 million (2022).
- Per our database at Business Quant, Aclaris Therapeutics' Payables skyrocketed by 10033.32% in 2023 and then crashed by 4717.28% in 2024.
- Aclaris Therapeutics' Payables (Quarter) stood at $10.0 million in 2021, then grew by 3.67% to $10.4 million in 2022, then decreased by 14.23% to $8.9 million in 2023, then plummeted by 47.17% to $4.7 million in 2024, then soared by 95.88% to $9.2 million in 2025.
- Its Payables stands at $9.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $6.4 million for Q1 2025.